Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate

American Journal of Ophthalmology

Volumn 121, Issue 3, 1996, Pages 291-296

  Hemady, R K ^a   Sinibaldi, V J ^a   Eisenberger, M A ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN; HYDROCORTISONE; LUBRICATING AGENT; SURAMIN;

ADULT; AGED; ARTICLE; DRUG BLOOD LEVEL; EYE TOXICITY; FOREIGN BODY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KERATOPATHY; LACRIMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REFRACTION ERROR; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 0029976138     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(14)70277-6     Document Type: Article

References (19)

1. F. Hawking Suramin: with special reference to onchocerciasis Adv Pharmacol Chemother 15 1978 289 322
2. Webster LT Jr. Drugs used in the chemotherapy of protozoal infections A Goodman-Gilman TW Rall AS Nies P Taylor Goodman and Gilman's the pharmacologic basis of therapeutics 8th ed. 1990 Pergamon Press New York 1008 1017
3. E. De Clerq Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses Cancer Lett 8 1979 9 22
4. M Popovic R Yarchoan S Matsushita RC Gallo S. Broder Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III Science 226 1984 172 174
5. BD Cheson AM Levine D Mildvan LD Kaplan P Wolfe J Rios Suramin therapy in AIDS and related disorders: report of the U.S Suramin Working Group. JAMA 258 1987 1347 1351
6. CA Stein RV La Rocca R Thomas N McAtee CE Myers Suramin: an anti-cancer drug with a unique mechanism of action J Clin Oncol 7 1989 499 508
7. JP Armand E. Cvitkovic Suramin: a new therapeutic concept Eur J Cancer 26 1990 417 419
8. C Myers M Cooper C Stein R LaRocca MM Walther G Weiss Suramin: a novel growth factor antagonist with activity in hormone refractory metastatic prostate cancer J Clin Oncol 10 1992 881 889
9. MA Eisenberger LM Reyno DI Jordell VJ Sinibaldi EJ Zuhowski LH Lowitt Suramin, an active drug for prostate cancer: interim observations in a phase I trial J Natl Cancer Inst 85 1993 611 621
10. M. Hosang Suramin binds to platelet derived growth-factor and inhibits its biological activity J Cell Biochem 29 1985 265 273
11. G Constantopoulos S Rees BG Cragg JA Barranger RO Brady Effect of suramin on the activities of degradative enzymes of sphingolipids in rats Res Commun Chem Pathol Pharmacol 32 1981 87 97
12. G Constantopoulos S Rees BG Cragg JA Barranger RO Brady Experimental animal model of mucopolysaccharidosis: suramin induced glycosaminoglycan and sphingolipid accumulation in the rat Proc Natl Acad Sci U S A 77 1980 3700 3704
13. FT Fraunfelder SM Meyer Drug-induced ocular side effects and drug interactions 3rd ed. 1989 Lea and Feibiger Philadelphia 66 67
14. TA Burch LL Ashburn Experimental therapy of onchocerciasis with suramin and hetrazan Am J Trop Med 31 1951 617 625
15. SA Teich S Handwerger U Mathur-Wagh S Yancovitz RJ Desnick D. Mildvan Toxic keratopathy associated with suramin therapy N Engl J Med 314 1986 1455 1456
16. EJ Holland CA Stein AG Palestine R LaRocca Chan C-C T Kuwabara Suramin keratopathy Am J Ophthalmol 106 1988 216 220
17. DI Jordell LM Reyno R Sridhara MA Eisenberger KH Tkaczuk EG Zuhowski Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentrations in patients with prostate cancer J Clin Oncol 12 1994 166 175
18. RJ Baldessarini Drugs and the treatment of psychiatric disorders A Goodman—Gilman TW Rall AS Nies P Taylor Goodman and Gilman's the pharmacologic basis of therapeutics 8th ed. 1990 Pergamon Press New York 383 435
19. JM Collins RW Klecker Jr R. Yarchoan Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection J Clin Pharmacol 26 1986 22 26